Evidence map›Paper›PMID 18000167›Full record

Trial reportBlood2008

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.

Beverly J Lange, Franklin O Smith, James Feusner, Dorothy R Barnard, Patricia Dinndorf, Stephen Feig, Nyla A Heerema, Carola Arndt, Robert J Arceci, Nita Seibel and 6 more

Open access · bronzeAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 8 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 8 syntheses or guidelines pooled it, 272 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008
    Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 2 countries.

Beverly J LangeUniversity of Pennsylvania School of Medicine and the Children's Hospital of Philadelphia, Division of Oncology, Philadelphia, PA, USA. lange@email.chop.edu
Franklin O Smith
James Feusner
Dorothy R Barnard
Patricia Dinndorf
Stephen Feig
Nyla A Heerema
Carola Arndt
Robert J Arceci
Nita Seibel
Margie Weiman
Kathryn Dusenbery
Kevin Shannon
Sandra Luna-Fineman
Robert B Gerbing
Todd A Alonzo
Arcadia · USUniversity of California, Los Angeles · USCalifornia Pacific Medical Center · USChildren's Hospital of Philadelphia · USChildren's National · USCincinnati Children's Hospital Medical Center · USColumbus State Community College · USIzaak Walton Killam Health Centre · CAJohns Hopkins University · USMayo Clinic in Arizona · USUC Davis Children's Hospital · USUnited States Food and Drug Administration · USUniversity of California, San Francisco · USUniversity of Minnesota · US

Funding

COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
CHILDRENS CANCER STUDY GROUP CHAIRMAN'S GRANTU10CA013539 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI REAMAN, GREGORY H · 1985 to 2002
$43.1M
NCI NIH HHS CA 13538NCI NIH HHS CA 13539NCI NIH HHS CA 98543NCI NIH HHS U10 CA098543
6 · The paper itself

Abstract

CCG-2961 incorporated 3 new agents, idarubicin, fludarabine and interleukin-2, into a phase 3 AML trial using intensive-timing remission induction/consolidation and related donor marrow transplantation or high-dose cytarabine intensification. Among 901 patients under age 21 years, 5-year survival was 52%, and event-free survival was 42%. Survival improved from 44% between 1996 and 1998 to 58% between 2000 and 2002 (P = .005), and treatment-related mortality declined from 19% to 12% (P = .025). Partial replacement of daunomycin with idarubicin in the 5-drug induction combination achieved a remission rate of 88%, similar to historical controls. Postremission survival was 56% in patients randomized to either 5-drug reinduction or fludarabine/cytarabine/idarubicin. For patients with or without a related donor, respective 5-year disease-free survival was 61% and 50% (P = .021); respective survival was 68% and 62% (P = .425). Donor availability conferred no benefit on those with inv(16) or t(8;21) cytogenetics. After cytarabine intensification, patients randomized to interleukin-2 or none experienced similar outcomes. Factors predictive of inferior survival were age more than 16 years, non-white ethnicity, absence of related donor, obesity, white blood cell count more than 100 000 x 10(9)/L, -7/7q-, -5/5q-, and/or complex karyotype. No new agent improved outcomes; experience may have contributed to better results time.

Indexed as

AdolescentAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolFemaleHumansIdarubicinInfantInfant, NewbornInterleukin-2Leukemia, Myeloid, AcuteMalePrognosisSurvival RateTreatment OutcomeVidarabinefludarabineIdarubicinInterleukin-2Vidarabine

Identifiers

PMID18000167
PMCPMC2214754
OpenAlexW2018591383

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.